Shield Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Shield Therapeutics has a total shareholder equity of $541.0K and total debt of $19.7M, which brings its debt-to-equity ratio to 3637.5%. Its total assets and total liabilities are $46.8M and $46.2M respectively.
Key information
3,637.5%
Debt to equity ratio
US$19.68m
Debt
| Interest coverage ratio | n/a |
| Cash | US$8.10m |
| Equity | US$541.00k |
| Total liabilities | US$46.22m |
| Total assets | US$46.76m |
Recent financial health updates
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Recent updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Financial Position Analysis
Short Term Liabilities: STX's short term assets ($27.8M) exceed its short term liabilities ($26.5M).
Long Term Liabilities: STX's short term assets ($27.8M) exceed its long term liabilities ($19.7M).
Debt to Equity History and Analysis
Debt Level: STX's net debt to equity ratio (2140.5%) is considered high.
Reducing Debt: STX's debt to equity ratio has increased from 0% to 3637.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STX has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: STX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 32.1% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:29 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shield Therapeutics plc is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Stuart Harris | Cavendish |
| Alexander Pye | Cavendish |